H2020Индивидуална стипендия2022–2024

BIOMA · Bacteriocins Impact on Obesity and MicrobiotA

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2022-02-01 → 2024-01-31
Финансиране от ЕС
184 591 €
Участници
1
Схема
MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Бактериоцините (антимикробни пептиди) се изследват за това как променят състава на чревните бактерии и метаболизма при затлъстяване. Това е важно, защото специфичното им действие може да помогне за разработването на нови методи за терапия при това заболяване.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Bacteriocins Impact on Obesity and MicrobiotA

There is a strengthening link between the gut microbiota with complex metabolic conditions like obesity. In the present world scenario, obesity has almost attained the level of a pandemic and is progressing at a rapid rate. More than 500 million people across the world live with the stigma of this disease, which shows the severity of its incidence and the challenges confronting health practitioners. Since the gut microbiota is an environmental regulator of fat storage and adiposity, alterations of the gut microbiota composition has been implicated as a contributory factor in obesity-related metabolic dysregulation. This has been reported in both animal and human studies, where the microbiota is characterized by reduced diversity. Bacteriocins are antimicrobial peptides produced by bacteria of many genera that can have a narrow or broad spectrum of activity. Many producer strains are generally regarded as safe (GRAS) or have qualitative presumption of safety (QPS). Unlike broad spectrum antibiotics that can significantly impact microbiota composition, bacteriocins are often very specific and can kill target organisms without causing collateral damage to host bacterial populations. There is sound evidence suggesting that bacteriocin-producing bacteria can be used to modify the gut microbiota, which makes bacteriocins and bacteriocin-producer strains an interesting strategy to prevent or treat diseases like obesity, which is associated with changes in the microbiota. The aim of BIOMA was to study the impact of different bacteriocin-producing strains on the composition of the gut microbiota and on metabolic function, to determine if they can be suitable as a possible therapeutic intervention to impact on obesity. This project provided rigorous experimental results on how bacteriocin production can effectively inhibit specific target populations and their impact on other gut microbes. By using bacteriocin-producing strains (Bac+) and their corresponding bacteriocin-negative mutants (Bac-), it was possible to assess the effect of bacteriocin production on human gut-derived microbial communities. While the gut microbiota is a realistic target for addressing obesity-related metabolic dysfunction, it has been suggested that the specificity of the antimicrobial agent employed may be critical. Some narrow spectrum bacteriocins are reported to have the potential to modulate gut health by elimination of specific pathogens. On the other hand, though broad spectrum bacteriocins can have a detrimental effect on the resident intestinal populations, they have exhibited promise with respect to their ability to improve metabolic health. Based on this, we selected a set of bacteriocins from different classes, subclasses and spectrum range. We proposed to work with bacteriocin-producing strains instead of the pure peptide for two main reasons; 1) bacteriocin-producing organisms provide a mean of delivering bacteriocins in the anaerobic environment of the gut and 2) the use of bacteriocin-producing cultures in functional foods is more cost effective than using pure peptide and is subject to less regulatory control. The main output from BIOMA was a panel of isogenic L. lactis strains that effectively produce bacteriocins from different classes and spectrum of activity and their corresponding non-producing controls. These strains have valuable potential to be used in both food and pharmaceutical industries as microbiome-editing tool. We assessed the behaviour of gut-derived communities over time and experimentally evaluated how the system is impacted by different bacteriocin producers. We established that the composition of the community changes in response to the presence of either broad- or narrow-spectrum bacteriocin producers and confirmed that there are significant off-target effects. These effects were analysed considering the inter-species interactions, providing a comprehensive insight into the possible mechanisms by which bacterial communities can be shaped by bacteriocins (published in Front. Microbiol; 2023).

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Alterations of the gut microbiota are implicated as a contributory factor in obesity-related metabolic dysregulation. Bacteriocins are antimicrobial peptides produced by bacteria of many genera, including several probiotic strains. These peptides are often very specific and can kill target species without causing collateral damage to host bacterial populations. Since bacteriocins are gaining credibility as precise modulators of the human microbiome, bacteriocin-producer strains are an interesting strategy to address obesity prevention and/or treatment. However, rigorous experimental methods are required to assess this. The aim of BIOMA is to study the impact of a set of different bacteriocin-producing strains with probiotic traits, on the composition of the gut microbiota and on metabolic abnormalities in obesity, through the use of wild type strains and derived mutants that no longer produce the bacteriocins. The proposal involves two complementary approaches: 1) In vitro fermentation systems that simulates the anaerobic and dynamic environment of the distal colon will be used to assess the effect of bacteriocins production on taxonomic profiles and diversity of gut microbial populations. 2) In vivo male and female murine models will be used to study changes in microbiota and whether these changes are associated with a reduction in body weight gain and an improvement in inflammatory and metabolic profiles. A secondment at Artugen (interface of academia and industry) will be a first step to face the challenging incorporation of bacteriocin-producing probiotics into foods and pharmabiotics. From a clinical perspective, the under-utilization of bacteriocins can be ascribed to a lack of awareness of what they can achieve. The outcome of BIOMA will impact clinical practice in the foreseeable future, providing an overview of the potential of bacteriocins as microbiota modulators and as a possible strategy in the prevention/management of obesity and metabolic disorders.

Оригинален текст от CORDIS (на английски).

Участници

  • UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK · CorkКоординаторИрландия

Връзки

Данни: CORDIS, © Европейски съюз